Microbot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications

Core Insights - The company has received a new patent for its LIBERTY Endovascular Robotic System, bringing its total to 12 granted patents globally and 57 pending applications, which enhances its intellectual property portfolio [1][2] - The new patent allows for modular capabilities in the robotic system, potentially expanding its application to a wider range of endovascular procedures, thereby increasing the Total Addressable Market (TAM) [1][2] - The company aims to address over 6 million annual endovascular procedures in the U.S., significantly higher than the current estimate of 2.5 million procedures [2][3] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics and improving patient care globally [4] - The company has developed the first single-use, fully disposable endovascular robotic system, which aims to remove traditional barriers to accessing advanced robotic systems [4]